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1. Introduction
Although the overall incidence of gastric cancer is decreasing worldwide, it is the main
cause of cancer death both worldwide and in East Asia including Japan. Gastric cancer is
histologically divided into two types, intestinal and diffuse types (Lauren, 1965). Helicobact‐
er pylori (H. pylori) infection is considered to be a major risk factor for the development of
intestinal-type gastric cancer (Correa, 1990; Sipponen & Hyvärinen, 1993; International
Agency for Research on Cancer [IARC], 1994; Graham, 2000; Uemura et al., 2001). It has
been postulated that H. pylori infection causes chronic gastritis, gastric atrophy, usually with
gastric intestinal metaplasia (IM) and dysplasia, and finally gastric cancer. The stepwise
course of this inflammatory process, which usually continues over decades, has been de‐
fined as a sequence of histological events that confer an increasing risk of malignant trans‐
formation, as described in Correa’s hypothesis (Correa, 1995). Long-term interactions
between H. pylori infection and human increase the risk for precancerous lesions such as
atrophic gastritis and IM (Peek & Blaser, 2002; Mera et al., 2005). Based on several long-term
prospective studies involving large groups of patients, it is believed that eradication of H.
pylori infection may prevent the development of gastric cancer (Uemura et al., 2001; Mera et
al., 2005; You et al., 2000; Take et al., 2005). According to a prospective, randomized, place‐
bo-controlled, population-based study from China, H. pylori eradication significantly de‐
creased the development of gastric cancer in participants without precancerous lesions, i.e.,
gastric atrophy, IM, or gastric dysplasia (Wong et al., 2004). Furthermore, it has been report‐
ed from Japan that H. pylori treatment reduces the risk of developing new gastric carcinoma
in patients who have a history of gastric cancer and are thus at high risk for such develop‐
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ment (Fukase et al., 2008). On the other hand, it is evident that gastric cancer still occurs to
some degree after endoscopic resection and successful eradication of H. pylori (Wong et al.,
2004; Fukase et al., 2008). Therefore, establishment of predictable markers for the identifica‐
tion of patients at high risk for recurrent gastric cancer development despite eradication of
H. pylori infection is clinically needed.
Gastric cancer develops through the accumulation of molecular alterations (Tamura, 2006).
Current knowledge of the molecular mechanisms underlying gastric carcinogenesis indicates
that two major genetic instability pathways are involved in the pathogenesis of gastric cancer:
microsatellite instability (MSI), and chromosome instability, including loss of heterozygosity
(Lengauer et al., 1998). We have recently reported that genetic instability in IM may be associat‐
ed with gastric carcinogenesis (Tanaka A et al., 2006; Zaky et al., 2008; Watari et al., 2012). Pre‐
vious  reports  have shown that  MSI  may play an important  role  in  the  development  of
synchronous or metachronous gastric cancer (MGC) and that it may be used clinically as a mo‐
lecular marker for the prediction of multiple gastric cancers (Miyoshi et al., 2001; Hasuo et al.,
2007). DNA methylation changes in cancer cells are characterized by regional CpG island hy‐
permathylation and generalized genomic hypomethylation. Epigenetic inactivation of tumor-
related genes by promoter hypermethylation is increasingly recognized to play an important
role on tumorigenesis (Laird, 2005; Robertson, 2005). Previous reports on promoter hyperme‐
thylation showed that epigenetic alterations are frequently observed in precancerous lesions
as well as in gastric cancer (Kang et al., 2001; To et al., 2002; Chan et al., 2006; Leung et al., 2006;
Perri et al., 2007; Dong et al., 2009; Park et al., 2009).
Das et al. have developed a novel monoclonal antibody (mAb), Das-1 (formerly known as
7E12H12, IgM isotype), which specifically reacts with the colonic epithelium (Das et al., 1987).
We have reported that IM of a colonic phenotype detected by mAb Das-1, is strongly associ‐
ated with gastric cancer, thus suggesting that mAb Das-1 positivity in IM could be a sensi‐
tive and specific marker related to gastric carcinogenesis (Mirza et al., 2003; Watari et al.,
2008). Furthermore, we have recently shown that H. pylori eradication does not reduce the
histological IM score, but changes the cellular phenotype of IM, as identified by this mAb in
a prospective, 4-year follow-up study (Watari et al., 2008).
Epidemiological data on pre-malignant lesions such as H. pylori-related IM are relevant for
predicting intestinal-type gastric cancer and for evaluating screening and surveillance prac‐
tices (Mirza et al., 2003; Watari et al., 2008). We followed patients who received and did not
receive H. pylori treatment after endoscopic resection for early gastric cancer for 1 year, and
then examined the changes in MSI and mAb Das-1 in IM in response to H. pylori therapy.
Here we show our study as to whether these biomarkers are predictive markers of MGC de‐
velopment after H. pylori treatment.
2. Patients and methods
We performed a hospital-based, case-control study of 75 patients, including 50 mucosal can‐
cer patients who had undergone endoscopic resection (Group DYS), and 25 age- and sex-
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matched chronic gastritis patients for whom H. pylori had been successfully eradicated
(control). In this study, the patients with duodenal ulcer only were excluded because most
of duodenal ulcers were categorized as ‘antral predominat gastritis’ (Uemura et al., 2001) or
‘non-atrophic gastritis’ (Mera et al., 2005), which is considered to be a low risk group of gas‐
tric cancer. Additionally, Group DYS patients were divided into 2 groups: 25 successfully H.
pylori-eradicated (eradicated group) and 25 un-eradicated patients (persistent group). Mu‐
cosal gastric cancer was defined as any cancer in which invasion was limited to the mucosa
based on Japanese criteria (Japanese Gastric Cancer Association. Japanese Classification of
Gastric Carcinom, 2010). In all patients, biopsy specimens were taken to assess H. pylori in‐
fection, two each from the greater curvature of the antrum and the greater curvature of the
corpus. The presence of H. pylori status was determined by a positive result for either or
both Wartin-Starry staining or H. pylori culture. For eradication, patients were treated with
lansoprazole (30 mg), amoxicillin (750 mg), and clarithromycin (400 mg), each taken twice
daily for 1 week. All patients in the eradicated group underwent endoscopic resection for
their mucosal cancer and then received treatment for H. pylori. All patients were followed
for 1 year. In patients from the eradicated group and control (chronic gastritis), clearance of
H. pylori was confirmed by negative results by both Wartin-Starry staining and H. pylori cul‐
ture at a follow-up endoscopy.
3. Intestinal metaplasia
All IM cases investigated here were goblet cell metaplasia, namely incomplete-type IM ob‐
tained from the antrum (Filipe et al., 1994). Serial sections (4 µm) were made, and consecu‐
tive sections were used for histologic examination by H&E staining and for
immunohistochemistry.
3.1. DNA extraction
From paraffin-embedded blocks, two 7-µm tissue sections were cut. DNA was extracted
from the IM samples. In this DNA extraction procedure, the sample was precisely microdis‐
sected under microscopic visualization using a PALM MG III Laser Capture Microdissection
System (MEIWAFOSIS, Tokyo, Japan) to avoid DNA contamination of inflammatory or stro‐
mal cell nuclei based on the previously described methodology (Tanaka et al., 2006; Zaky et
al., 2008; Watari et al., 2012).
3.2. Analysis of MSI
The MSI was analyzed as reported previously (Tanaka et al., 2006; Zaky et al., 2008; Watari
et al., 2012). We examined five microsatellite markers (two mono- and three dinucleotide re‐
peats) for MSI based on the revised Bethesda panel (Umar et al., 2004) as follows: 2p
(BAT26), 4q (BAT25), 2p (D2S123), 5q (D5S346), and 17p (D17S250). Briefly, polymerase
chain reaction (PCR) amplification was carried out in a reaction volume of 10 µL, which con‐
tained 100 ng of genomic DNA, 1X PCR buffer (Perkin Elmer Applied Biosystems, Foster
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City, CA), 200 µmol/L of dNTP, 600 µmol/L of each primer, and 1.5 units of AmpliTaq Gold
polymerase (Perkin Elmer). The MgCl2 concentration was 1.5 mmol/L. The following PCR
cycle conditions were used for amplification: 95˚C for 10 min, 30 cycles of 95˚C for 45 sec,
55˚C for 1 min, and 72˚C for 30 sec. The PCR products were evaluated for MSI by capillary
electrophoresis using an ABI prism 310 Genetic Analyzer (Perkin Elmer) and automatic siz‐
ing of the alleles using a Gene Scan (Applied Biosystems). The MSI status was judged ac‐
cording to previous reports (Tanaka et al., 2006; Zaky et al., 2008; Watari et al., 2012). MSI
was defined as positive when unequivocal extra peak bands in tumor DNA were observed
that differed by multiples of 2 base pairs in dinucleotide markers or 1 base pair in mononu‐
cleotide markers from DNA in normal mucosa, and was also characterized by the appear‐
ance of additional alleles in the tumor DNA. The former type MSI was judged as the minor
pattern (Figure 1A) and the latter type as the major pattern (Figure 1B), as reported previ‐
ously (Tanaka et al., 2006; Zaky et al., 2008; Watari et al., 2012). IM was defined as having
high MSI (MSI-H) when unstable loci were observed in two or more of five microsatellite
markers and as having low MSI (MSI-L) when an unstable locus was observed in only one
of the five markers studied based on the criteria established in 2002 (Umar et al., 2004). The
lesion was considered microsatellite stable (MSS) if no unstable loci were found. The MSI
phenotype was categorized into two groups, MSI-H and MSI-L/MSS. In our study, a sample
was defined as MSI only when it qualified as MSI-H.
Figure 1. Examples of microsatellite instability (MSI) were detected in intestinal metaplasia (IM) by high-resolution flu‐
orescent microsatellite analysis. DNA was isolated from IM and matching normal mucosa without IM (N). (A) Repre‐
sentative case of a minor pattern of MSI on D17S250. MSI is seen as an unequivocal extra peak shift (arrow) compared
with normal mucosa. (B) Representative case of a major pattern of MSI on BAT26. MSI is characterized by the appear‐
ance of multiple additional alleles (arrows).
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4. Immunoperoxidase assays with mAb Das-1
Serial sections were stained with mAb Das-1 using sensitive immunoperoxidase assays as
described previously (Watari et al., 2012; Das et al. 1987; Mirza et al., 2003; Watari et al.,
2008). Reactivity to mAb Das-1 was considered positive if cells were stained a crisp golden
brown. A substantial number of cells and more than one gland had to be reactive to this
mAb before a specimen was considered positive. If only an occasional goblet cell was
stained, the sample was defined as negative (Watari et al., 2012; Das et al. 1987; Mirza et al.,
2003; Watari et al., 2008; Das et al., 1994).
4.1. Statistical analysis
The data were assessed by the Mann-Whitney U-test, the chi-square test, and Fisher’s exact
test. Statistical significance was defined by a p value of <0.05. Odds ratios (ORs) and corre‐
sponding 95% confidence intervals (CIs) for each biomarker (MSI and mAb Das-1 reactivity)
by a case-control study were calculated using StatView Ver. 5.0 for Macintosh (SAS Institute
Inc., North Carolina, USA). Risk factors with a p value of < 0.10 in univariate analyses were
included in a multiple logistic regression model and analyzed using the backward ap‐
proach. The 95% CI of the OR was used to assess the statistical significance at the conven‐
tional level of 0.05.
4.2. Results
4.2.1. Patient characteristics
The mean ages of patients in the eradicated, persistent, and control groups were 70.8 (range
54-79), 70.9 (range 59-80), and 69.5 (range 62-77), respectively. Male patients made up 76% of
the eradicated group, 92% of the persistent group, and 80% of the control group. There were
no significant differences in age and gender among the three groups.
5. MSI and mAb Das-1 reactivity in IM
The observed incidences of MSI were 28.0% (14 of 50) in Group DYS and 8.0% (2 of 25) in
the control; these results were significantly different (p<0.05). Similarly, mAb Das-1 reactivi‐
ty of IM was also more frequently observed in Group DYS (66.0%, 33 of 50) than in the con‐
trol (32.0%, 8 of 25) (p=0.07) (Table 1). We analyzed the strength of the association between
gastric cancer and advanced age (70 years or older), male gender, MSI and mAb Das-1 reac‐
tivity by calculating univariate and multivariate logistic regression (Table 2). MSI and mAb
Das-1 reactivity were associated with gastric cancer in the univariate analysis. In the multi‐
variate logistic regression analysis, MSI and Das-1 reactivity were strong and independent
factors (OR=7.09, 95% CI 1.27-39.6, p=0.03 in MSI; OR=4.96, 95% CI 1.64-15.0, p=0.005 in
Das-1 reactivity). The sensitivity, specificity, and positive predictive value of MSI and mAb
Das-1 reactivity of IM for gastric cancer were 28.0% (14 of 50), 92.0% (23 of 25), 87.5% (14 of
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16), and 66.0% (33 of 50), 68.0% (17 of 25), 80.5% (33 of 41), respectively. If at least one of
these 2 biomarkers was expressed in IM, those statistical calculations for gastric cancer be‐
came 78.0% (39 of 50), 60.0% (15 of 25) and 79.6% (39 of 49), respectively.
Microsatellite instability Das-1 reactivity
At initial After 1-year At initial After 1-year
Group DYS (n=50) 14 (28.0) * - 33 (66.0) ** -
Eradicated group (n=25) 7 (28.0) † 2 (8.0) † 16 (64.0) 12 (48.0) §
Persistent group (n=25) 7 (28.0) 6 (24.0) 17 (68.0) 18 (72.0) §
Control (n=25) 2 (8.0) * 1 (4.0) 8 (32.0) ** 4 (16.0)
* p<0.05, ** p<0.01, † p=0.07, § p=0.08, Numbers in parentheses are percentages.




p Odds ratio 95% CI p
Microsatellite instability 0.06 7.09 1.27-39.6 0.03
Das-1 reactivity 0.007 4.96 1.64-15.0 0.005
Table 2. Predictors for development of gastric cancer
6. Changes in MSI and mAb Das-1 reactivity after H. pylori treatment
The incidence of MSI in IM 1 year after H. pylori treatment tended to decrease from 28.0% (7
of 25) to 8.0% (2 of 25) in the eradicated group (p=0.07), while there was no significant
change in the persistent group during the follow-up period. The incidence of MSI also de‐
clined in the control, but the difference between pre- and post-eradication rates was not sig‐
nificant (Table 1). Similarly, the immunoreactivity of IM against mAb Das-1 decreased from
64.0% (16 of 25) to 48.0% (12 of 25) in the eradicated group, and from 32.0% (8 of 25) to 16.0%
(4 of 25) in the control in response to H. pylori treatment; the difference in each group be‐
tween pre- and post-treatment rates was not significant. In contrast, the incidence of the re‐
activity in the persistent group showed no changes at the 1-year follow-up. One year after
treatment, the incidence of mAb Das-1 reactivity tended to be lower in the eradicated group
than in the persistent group (p=0.08) (Table 1).
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7. Newly developed gastric cancer after treatment
MGC was defined as a new carcinoma occurring at a previously uninvolved site in the
stomach found more than 1 year after endoscopic resection. We encountered 13 MGCs that
developed after endoscopic resection from January 1996 to July 2008, which included 3
(3.8%) of 79 patients for whom H. pylori had been eradicated and 10 (9.4%) of 106 patients
who were un-eradicated. However, no newly developed gastric cancer was identified in 290
chronic gastritis patients in the same period. Three of 13 cases did not reveal IM in the biop‐
sy at the time of MGC detection. The characteristics of the remaining 10 patients that devel‐
oped gastric cancer after endoscopic treatment are shown in Table 3. Intriguingly, all
patients showed positive for either MSI or mAb Das-1 reactivity in IM.
At the time of MGC detection







1 Eradicatedgroup 77 M 2.5 5.2 + +
2 Eradicatedgroup 78 M 2.7 3.4 - +
3 Eradicatedgroup 68 M 1.1 1.8 - +
4 Persistentgroup 65 M NA 1.8 + -
5 Persistentgroup 71 F NA 1.8 + -
6 Persistentgroup 76 M NA 1.1 + +
7 Persistentgroup 74 M NA 1.2 + +
8 Persistentgroup 79 M NA 1.3 - +
9 Persistentgroup 71 M NA 1.0 - +
10 Persistentgroup 81 M NA 7.3 + -
Table 3. Clinical characteristics of metachronous gastric cancer (MGC) after endoscopic resection
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One of the patients (Case 1) in Group DYS presented a flat, elevated lesion at the antrum
(Figure 2A). Endoscopic resection was performed on this lesion, and the histological diagno‐
sis was mucosal cancer. Then, the patient received treatment for H. pylori. Thirty months af‐
ter eradication, at the follow-up endoscopy, a new cancer was found at the lesser curvature
of the corpus (Figure 2B and 2C). Interestingly, this patient lacked MSI prior to eradication
but exhibited MSI after H. pylori therapy, while mAb Das-1 reactivity was positive both be‐
fore and after eradication (Figure 2D and 2E).
Figure 2. A) Endoscopic findings showed a flat elevated gastric cancer (arrow) at the posterior wall of the antrum. H.
pylori was eradicated after endoscopic resection to the lesion. (B) At 30 months after eradication, a new lesion was
found at the lesser curvature of the lower body of the stomach (arrowhead). (C) The resected sample was diagnosed
histologically as mucosal cancer (×100). (D) IM in biopsy obtained from the antrum reacted with Das-1 (×200) prior to
H. pylori treatment, and (E) the reactivity of Das-1 in IM was also demonstrated at the time a new gastric cancer was
found following eradication (×200).
8. Discussion
Recent prospective randomized trial from Japan proved that H. pylori eradication signifi‐
cantly prevents the development of MGC after endoscopic mucosal resection to early gastric
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cancer (Fukase et al., 2008). In contrast, another Japanese retrospective study showed that
the incidence of MGC did not differ between the eradicated group and the persistent groups
during a follow-up period of as long as 11.1 years (Maehata et al. 2012). Nonetheless, new
gastric cancer does sometimes develop after successful treatment of H. pylori infection in
both reports (Wong et al., 2004; Maehata et al. 2012). These results indicate that once gastric
cancer has developed in the stomach a first time, the background mucosa has increased po‐
tential of developing MGC (Wong et al., 2004; Zaky et al., 2008; Maehata et al. 2012). There‐
fore, efficient strategies to identify individuals who are at a “high risk” for MGC after H.
pylori treatment are very much needed. We found in this study that MSI or mAb Das-1 reac‐
tivity in IM may serve independently as biomarkers to predict the development of gastric
cancer regardless of H. pylori eradication.
It has previously been reported that MSI possibly plays a role in early events leading to gas‐
tric carcinogenesis (Chung et al., 1996; Buonsanti et al., 1997). Until now, we have also re‐
ported that genetic instability is frequently observed in the progression of IM in chronic
gastritis patients and of IM in patients with gastric cancer and a cancerous area (Tanaka et
al., 2006; Zaky et al., 2008). In this case-control study, the frequency of MSI in IM was signifi‐
cantly higher in Group DYS than in the control. These findings indicate that MSI may be a
useful marker in identifying “high risk” IM that may develop into gastric cancer. It has since
been reported that MSI may be associated with the inflammation from the standpoint of
view of the investigation from patients with ulcerative colitis (Brentnall et al., 1996) or
chronic hepatitis (Kondo et al., 2000). In the present study, MSI changed, becoming stable in
response to the improvement of inflammation following eradication; these findings may in‐
dicate that inflammation of the stomach affects the presence of MSI. On the other hand,
there is an interesting report by Kashiwagi et al. (Kashiwagi et al., 2000) in which MSI in
gastritis, adenoma, and adenocarcinoma were examined retrospectively. According to their
results, in all patients (n=6) with gastric adenoma or adenocarcinoma showing MSI, identical
MSI patterns had been observed at the stage of gastritis, 1.5 to 7 years before the final diag‐
nosis of adenocarcinoma. Thus, they concluded that MSI in chronic gastritis mucosa may
identify patients at risk of developing gastric adenoma and cancer. Taking into account their
results and ours, MSI expressed in IM, regardless of successful H. pylori eradication may be
a predictor for the risk of MGC development.
Consistent with our previous reports (Mirza et al., 2003; Watari et al., 2008), the current
study demonstrated that IM reactivity to mAb Das-1 is strongly associated with gastric can‐
cer. However, the reactivity did not show a statistically significant decrease at 1 year after H.
pylori eradication in the current study although our previous study showed a significant de‐
cline in mAb Das-1 positivity following treatment, up to 4 years (Watari et al., 2008). One of
the explanations for this discrepancy may be the difference in the length of follow-up. It
may be the case that a cellular phenotypic change by H. pylori treatment requires substantial
time in comparison with MSI. However, mAb Das-1 reactivity declined significantly more in
the eradicated group more than in the persistent group as of 1 year after H. pylori treatment.
Some individuals actually showed persistent immunoreactivity to mAb Das-1 after treat‐
ment as shown in the previous report (Watari et al., 2008). Importantly, seven (70%) of 10
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newly developed gastric cancers after endoscopic resection were positive for mAb Das-1 re‐
activity after eradication of H. pylori.
Based on our results, then, lesions that are newly or persistently positive for the markers in‐
cluding MSI or mAb Das-1 after H. pylori eradication are at a certain stage of progression of
IM, and may have passed the “point of no return” (Wong et al., 2004; Wright, 1998). It re‐
mains possible, therefore, that these are patients who are at high risk of developing gastric
cancer that may warrant more intensive endoscopic surveillance to detect early gastric can‐
cer. Wong et al. reported that eradication of H. pylori did not decrease the development of
gastric cancer in participants with precancerous lesions such as IM (Wong et al., 2004). In
contrast to their report, our results may provide an important clue to the pathogenesis of the
observed reduction of gastric cancer following H. pylori eradication in some patients with IM
from the perspective of MSI or the cellular phenotype related to carcinogenesis.
It is intriguing that all newly developed cancers occurred only from Group DYS, with none
from the control, although the number of cases investigated was small. This result indicates
that IM in the background mucosa in patients from Group DYS is in an advanced stage com‐
pared to that in the control (chronic gastritis), and has more malignant potential. According‐
ly, the accumulation of genetic alterations may be continued during the progression of IM.
Considering the results in a Japanese population from Take et al., gastric cancer developed
in 0.8% (8 of 944) of peptic ulcer patients cured of infection for up to 8.6 yr (mean 3.4 yr)
(Take et al., 2005). Moreover, a recent report from a multi-center, open-label, randomized
controlled trial from the Japan GastStudy Group suggested that eradication of H. pylori re‐
duced by approximately one-third the risk of new gastric cancer in patients with a history of
gastric cancer, but could not completely prevent cancer development (Fukase et al., 2008).
According to this report, the incidence of new gastric cancer development was 3.5% (9 of
255) during 3 yrs of follow-up after endoscopic resection, significantly different from that re‐
ported by Take et al. Taking the findings of these reports and ours into consideration, the
background gastric mucosa in patients who have a history of cancer may have more malig‐
nant potency in comparison to that in chronic gastritis patients. Thus, the molecular and cel‐
lular phenotypic backgrounds of IM can explain the pathogenesis of MGCs, even after
resection of tumors due to persistent uncorrected accumulated errors of DNA mismatch re‐
pair and colonic phenotype on IM.
Newly developed gastric cancers may be the result of occult gastric cancers that are not de‐
tectable at the previous endoscopy, but that have grown enough to be diagnosed at the fol‐
low-up. Regarding the definition of MGC after endoscopic resection, therefore, it may be
necessary to conduct follow-up for a long time, more than 1 year. In the current study, how‐
ever, the subset of IM with MSI or mAb Das-1 positivity has the possibility of developing
gastric cancer after even this relatively short period of time. Indeed, all patients who devel‐
oped new cancer showed positive for MSI or mAb Das-1 reactivity in IM (Table 3). The per‐
sistence of DNA damage and the colonic phenotype, as detected by mAb Das-1, may
identify the "at risk" group of patients with histological IM; thus, these biomarkers in the bi‐
opsy specimens of gastric mucosa may predict MGC development following H. pylori thera‐
py. In the current study, the number of patients analyzed may be small, particularly for the
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comparison of MSI and cellular phenotypes in the three different groups. Further investiga‐
tions on a larger series will be required in the future.
First of all, H. pylori should be absolutely eradicated for the prevention of MGC develop‐
ment. The efficacy of standard 7-14 day triple therapies is decreasing, mainly due to increas‐
ing primary bacterial resistance to antibiotics. Currently, the most effective treatments are
either the sequential regimen or the concomitant therapy. The sequential therapy was first
introduced in Italy in 2000 (Zullo et al., 2000). This regimen is a 10-day therapy, including a
simple dual therapy with a proton pump inhibitor (PPI) plus amoxicillin 1 g (both twice dai‐
ly) given for the first 5 days, followed by a triple therapy including a PPI, clarithromycin 500
mg, and tinidazole 500 mg (all given twice daily) for the remaining 5 days. Different antibi‐
otic combinations, administered together with a PPI, have been proposed in the last deca‐
des. Unfortunately, no available therapy is able to eradicate H. pylori in all treated patients.
Therefore, new drugs and novel therapeutic approaches are needed. It has been recently re‐
ported by a randomized clinical trial that simvastatin as adjuvant to standard therapy im‐
proves significantly the H. pylori eradication rate (Nseir et al., 2012). The search for novel
antibacterial therapies against H. pylori is a “work in progress” driven by the goal of pre‐
venting gastric cancer, and by worldwide increasing antibiotic resistance (Fiorini et al.,
2012).
We believe that MSI and mAb Das-1 reactivity may be reliable biomarkers to identify a sub‐
group of patients at sufficiently high risk of MGC after endoscopic resection to justify endo‐
scopic surveillance. According to recent reports, H. pylori eradication is able to significantly
reduce gene methylation thus delaying or reversing H. pylori-induced-gastric carcinogenesis
(Chan et al., 2006; Leung et al., 2006; Perri et al., 2007). It has been also reported that sonic
hedgehog methylation was detected more frequently in the high-risk group for gastric can‐
cer after H. pylori treatment (Shiotani et al., 2012). Further studies on genetic and epigenetic
alterations, are necessary to clarify the credibility of the markers in different regional popu‐
lations.
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